Publications

Il est fondamental pour nous de communiquer les résultats de nos recherches. Cette préoccupation se reflète dans le grand nombre de publications dans des revues influentes et dans les innombrables posters et participations aux principaux congrès internationaux, en particulier dans le domaine des neurosciences.

Ci-dessous, vous trouverez quelques exemples de publications, certaines signées ou cosignées par des scientifiques de BIAL.

Onglets

Efficacy and safety of eslicarbazepine acetate versus controlled-release carbamazepine monotherapy in newly diagnosed epilepsy: A phase III double-blind, randomized, parallel-group, multicenter study.

Trinka E, Ben-Menachem E, Kowacs PA, Elger C, Keller B, Löffler K, et al.

Publié dans: Epilepsia [Internet]. 2018;59(2):479–91.

Tolerability and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy in Patients Aged ≥ 65 Years with Focal Seizures

Costa R, Steinhoff B, Gama H, Ikedo F, Rocha JF, Soares-da-Silva P. Safety, Tolerability and Efficacy of Eslicarbazepine

Publié dans: Drugs Aging [Internet]. 2018;null–null.

Effects of adjunctive eslicarbazepine acetate on neurocognitive functioning in children with refractory focal-onset seizures.

Jóźwiak S, Veggiotti P, Moreira J, Gama H, Rocha F, Soares-da-Silva P.

Publié dans: Epilepsy & behavior : E&B [Internet]. 2018;81:1–11.

Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group phase III study.

Christian Elger.

Publié dans: Epilepsia. 2009;50(3):454–63.

Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy.

E. Ben-Menachem.

Publié dans: Epilepsy Res Suppl. 2010;89(2-3):278–85.

Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures.

A. Gil-Nagel.

Published: Acta Neurol Scand. 2009;120(5):281–7.

Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial.

Sperling MR, Abou-Khalil B, Harvey J, Rogin JB, Biraben A, Galimberti CA, et al..

Publié dans: Epilepsia [Internet]. 2015;56(2):244–53.

Long-term efficacy of opicapone in fluctuating Parkinson’s disease patients: A pooled-analysis of data from two Phase 3 clinical trials and their open-label extensions.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P.

Publié dans: Eur J Neurol [Internet]. 2019;null–null.

Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease

Ferreira JJ, Lees AJ, Poewe W, Rascol O, Rocha JF, Keller B, et al.

Publié dans: Neurology [Internet]. 2018;90(21):e1849–e1857.

Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.

Ferreira JJ.

Publié dans: Lancet Neurol. 2016;15(2):154–65.

Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.

Rocha JF, Falcão A, Santos A, Pinto R, Lopes N, Nunes T, et al.

Publié dans: Eur J Clin Pharmacol [Internet]. 2014;70(9):1059–71.

Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.

Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, et al.

Publié dans: JAMA Neurol [Internet]. 2017;74(2):197–206.

Préclinique

.

Effect of zamicastat in chronic treatment on right ventricle pressure overload in the rat monocrotaline lung injury model of pulmonary hypertension

Igreja, B., Pires, N., Moser, P. and Soares-da-Silva, et al.

Publié dans: Hypertension. 2016;68(Suppl. 1: AP238).

Effect of Chronic Treatment With Zamicastat on Right Ventricle Pressure Overload in the Rat Monocrotaline Lung Injury Model of Pulmonary Hypertension.

Igreja, B., Pires, N., Moser, P. and Soares-da-Silva, et al.

Publié dans: The FASEB Journal. 2017;31(1 Supplement 1070.7).

Effect of zamicastat, a dopamine beta-hydroxylase inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension.

Moura, E., Costa, C., Igreja B., Pires, et al.

Publié dans: European Respiratory Society Meeting. 2020.

The Dopamine Beta-Hydroxylase Inhibitor Zamicastat Improves Survival in the Rat Monocrotaline Model of Pulmonary Arterial Hypertension.

Bonifacio M.J., Moura E., Sousa F., Igreja B., Pires N., Soares-da-Silva P.

Publié dans: J Respir Crit Care Med. 2020;(201:A2088).

Zamicastat decreases cardiac arrhythmias in a rat model of pulmonary arterial hypertension.

Pires N., Igreja B., Magalhães L., Bonifácio M.J., Chevalier E., Soares-da-Silva P.

Publié dans: Pulmonary Hypertension. 2020.

BIA 5-1058 is a new noncompetitive dopamine-β-hydroxylase inhibitor.

Bonifacio M.J., Sousa F., Igreja B., Loureiro A.I., Wright L.C., Soares-da-Silva P.

Publié dans: Proceedings of the British Pharmacological Society. 2012.

In vitro Species Different Metabolism and CYP Phenotyping of Zamicastast.

Loureiro A.I., Rebouta J., Bonifácio M.J., Soares-da-Silva P.

Publié dans: FASEB J. 2020;34(S1):1–1.

Clinique

.

A Double-Blind, Randomised, Placebo-Controlled, Multiple Ascending Dose Study to Investigate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Zamicastat, in Healthy Male Volunteers.

Magalhães L., Rocha F., Falcão A., Gama H., Soares-da-Silva P.

Publié dans: American Journal of Respiratory and Critical Care Medicine. 2020;201:A3816.

A Randomized, Double-Blind, Placebo-Controlled and Open-Label, Active-Controlled, 4-Period Crossover Trial to Evaluate the Effect of Zamicastat on Cardiac Repolarization in Healthy Adult Males and Females Under Fed Conditions.

Gama H., Magalhães L., Santos A., Soares-da-Silva P.

American Journal of Respiratory and Critical Care Medicine. 2020;201:A3815.

Drug-drug interaction study between zamicastat and bosentan in healthy subjects.

Guimarães A., Santos A., Ferreira J., Magalhães L., Gama H., Soares da Silva P.

Chest. 2020;157(6):A382.

Drug-drug interaction study between zamicastat and sildenafil in healthy subjects.

Santos A., Ferreira J., Gama H., Magalhães P. Soares -da-Silva P.

European Respiratory Journal 2020 56: 1458.

Drug-drug interaction study between zamicastat and treprostinil in healthy subjects.

Magalhães L., Guimarães A.M.R., Gana H., Magalhães P., Soares-da-Silva P.

American Journal of Respiratory and Critical Care Medicine 2021;203:A3615.

×

Vous êtes sur le point de quitter le site web de BIAL.

BIAL assume l'entière responsabilité des contenus figurant sur son site web. En cliquant sur « CONTINUER » ci-dessous, vous serez redirigé(e) vers un site externe ne relevant pas de notre responsabilité.

ANNULER CONTINUER